Project Number 5P01AG022074-07 Agency/Funding Organization NIA Funding Year 2009 View Full Project Details for MICROGLIAL KYNURENINE PATHWAY AND SELECTIVE NEURONAL VULNERABILITY Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 9. Immunity and Inflammation b. Microglia Researcher and Organization Principal Investigator MUCHOWSKI, PAUL J Principal Investigator First Name PAUL J Principal Investigator Last Name MUCHOWSKI Awardee Organization J. DAVID GLADSTONE INSTITUTES Awardee State California Contact PI Country United States Project Detail FY Overall Cost $388,397 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis [AlzPED] Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model [AlzPED] Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model [AlzPED] Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.